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Abstract  
OBJECTIVES: Cortical thinning, previously identified during prodromal stages of AD, 
is a “candidate” biomarker implemented in AD clinical therapy trials. We have 
investigated the effect of donepezil treatment on cortical thickness in mild cognitively 
impaired subjects with the amnestic syndrome of the hippocampal type, a prodromal 
at risk group for progression to AD dementia.  
METHODS: Longitudinal analysis of a community-based multi-centric suspected 
prodromal AD cohort (92 placebo versus 81 donepezil) enrolled in a double-blind, 
randomized, placebo-controlled parallel group design using donepezil (10mg/day) has 
been conducted. The study started in November 2006 and was concluded in August 
2010. All subjects underwent two brain structural Magnetic Resonance Imaging (MRI) 
scans, at baseline and at the end of the trial. Structural MRI images have been 
processed using the automated pipeline for longitudinal segmentation and surface 
reconstruction implemented in FreeSurfer. The primary outcome measure of this post-
hoc study was the cortical thickness annualized percentage change (APC). 
RESULTS: The donepezil group exhibited reduced APC cortical thinning compared to 
placebo in the Rostral Anterior Cingulate (right: p = 0.048; and left: p = 0.032), the 
Orbitofrontal (right: p = 0.012 and left p < 0.048), and the right Inferior Frontal (p = 
0.022) cortices and in the right Insula (p = 0.010). These results were not statistically 
significant after Bonferroni correction likely due to insufficient power for cortical 
thickness measurements in the study group powered for the predefined hippocampus 
outcome. 
CONCLUSIONS: Our findings support the hypothesis that cortical thickness is a 
reliable candidate surrogate outcome in early pre-dementia AD trials. In addition, 
donepezil treatment may have an impact on cortical structure/morphology in areas 
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innervated by the medial and lateral cholinergic pathways.  
Clinical Trial Registration: ClinicalTrials.gov NCT00403520 
Key words: Cortical Thickness, Alzheimer’s Disease, MRI, Donepezil, Cholinergic 
system, Clinical Trials, prodromal AD, Mild Cognitive Impairment, Progression  
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Introduction  
The current approved treatments with cholinesterase inhibitors are generally 
considered as moderately and only symptomatically beneficial for late-stage AD 
dementia patients 1. Evidence of potential biological and disease-modifying 
properties of cholinesterase inhibitors is controversially and critically discussed. No 
agent tested in randomized clinical trials in Mild Cognitive Impairment (MCI) has met 
its primary efficacy objectives, measured by clinical rating instruments 2-10. 
To date, only one study investigating the use of in vivo biomarkers of AD in 
Donepezil clinical trial has been conducted 11. On the other hand, further clinical 
studies on structural imaging markers in MCI subjects have reported conflicting 
results 12-14.  
Although cortical-thickness represents a promising structural imaging end point in 
clinical trials, as it offers a direct assessment of effect sizes expressed in a 
meaningful metric, 15-17 no study has investigated the donepezil effect on the cortical 
mantle yet.  
This is a post hoc study based on the data collected in the context of the 
Hippocampus Study Clinical Trial (NCT00403520). The first aim of the trial was to 
investigate the effect of Donepezil treatment using the hippocampal rate of changes 
as primary outcome 14. Here, we are going to consider the impact of donepezil 
treatment on the thickness rate of change in suspected prodromal AD patients 
diagnosed using the Free and Cued Selective Reminding Test (FCSRT), a test 
allowing prognostication of prodromal AD within the group of MCI individuals 18, 19.   
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Methods 
Study Population 
Participants included in the present study were all the patients who performed a 
baseline and a follow-up MRI scan during the Hippocampus Study Clinical Trial 
(NCT00403520)14. The primary efficacy outcome of the Hippocampus Study was the 
annualized percentage change (APC) of total hippocampal volume measured by an 
automated segmentation method. In this post hoc analysis, we explored the effect of 
Donepezil on the cortical thickness. Each patients received at least 1 dose of double-
blind study medication, and had baseline and follow-up clinical and Magnetic 
Resonance Imaging (MRI) assessment. 
The details of the patient characteristics have been previously described 14. Briefly, a 
total of 332 patients were screened within the national network of Memory Resources 
and Research Centres (MRRC) consisting of 28 regional university expert centres 
with neurologists, geriatricians, neuropsychologists, biological and neuroimaging 
resources in each centre.  
Inclusion criteria were: 1) more than 50 years of age; 2) a progressive hippocampal 
amnestic syndrome defined by Free Recall  17 or Total Recall < 40 on the FCSRT; 
and 3) no dementia with a CDR stage of 0.5 and preserved cognition and functional 
performance. Subjects who met the eligibility criteria were enrolled in the 
randomization phase beginning with Visit 1. From the total population of individuals 
randomized in the clinical trial (103 Placebo and 113 Donepezil), for the present 
study we considered exclusively patients who performed MRI at baseline and at the 
end of the treatment (Placebo=92 and Donepezil= 82). 
Study Design 
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This was a multi-centre double-blind, randomized, placebo-controlled trial with a 
treatment period of 12 months. The sample power of the study was calculated 
according to the primary aim of the Hippocampus Study Clinical Trial, and not for the 
aim of the present study. The study started in November 2006 and was concluded in 
August 2010. At baseline visit, patients underwent a baseline MRI scan and a 
cognitive evaluation including: the Alzheimer’s Disease Assessment Scale-cognitive 
subscale, MCI version (ADAS-COG-MCI)20, Mini-Mental State Examination (MMSE), 
Modified Isaacs test score, California Verbal Learning Test (CVLT)21, Trial Making 
Tests (TMT) A and B22, and the Benton Test 23. Following baseline evaluation, 
patients were randomly assigned to one group out of two, corresponding to either 
active treatment or placebo (1 capsule of 5-mg donepezil daily for Weeks 0 to 6, then 
2 capsules of 5-mg donepezil [i.e., 10 mg] daily from Week 6 to Month 12 for double-
blind treatment; or 1 placebo capsule daily for Weeks 0 to 6, then 2 capsules daily 
from Week 6 to Month 12 for double-blind treatment, respectively). The study 
protocol was approved by the institutional review board of each site, and informed 
consent was obtained from all subjects.  
Acquisition of MR images 
Brain MRI scans were acquired in each centre at baseline and after at the end of 
treatment period. All the MRI were performed using 1.5 Tesla or 3 Tesla MRI scanners 
qualified by the central MRI analysis core at the Cogimage team, Centre de Recherche 
de l’institut du Cerveau et de la Moelle Épinière (CRICM). The sequences used in the 
present manuscript were 3D T1-weighted images. The 3D T1-weighted scan 
parameters for scans at 1.5T were: TR = 10 ms, TE = minimum, flip angle: 10, PREP 
time: 600, bandpass: 12.50 khz, axial orientation; 1.3mm slice thickness, contiguous 
(124 slices), Imaging matrix size: 256 x 256, Field of view: 240 x 240 ; for scans at 3T 
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were:  TR = 3.9 ms, TE = 2100 ms, flip angle: 15, PREP time: 1100 ms, sagittal 
orientation with 1 mm slice thickness, contiguous (144 slices), Acquisition matrix size: 
256 x 192, Field of view: 256 x 192. The expert neuroradiologist in charge of quality 
control verified artifacts of movements, ringing, wrap around and metal artifacts, 
moreover they attested that the sequences were acquired according to protocol 
parameters. After the quality control of images, one 3D T1-weighted scan was 
identified as corrupted and it was excluded from the all statistical and the neuroimaging 
analysis. 
 
Cortical Thickness Reconstruction and Surface Analysis  
To extract reliable thickness estimates, images were automatically processed with 
the longitudinal stream 24 in FreeSurfer (http://surfer.nmr.mgh.harvard.edu/) version 
5.1. Details on the longitudinal pipeline used to analyzing data are described at the 
following link (https://surfer.nmr.mgh.harvard.edu/fswiki/LongitudinalProcessing). 
Specifically an unbiased within-subject template space and image is created using 
robust, inverse consistent registration 25. Several processing steps, such as skull 
stripping, Talairach transforms, atlas registration as well as spherical surface maps 
and parcellations are then initialized with common information from the within-subject 
template, significantly increasing reliability and statistical power 26. Based on gyral 
and sulcal anatomy, the cortex was segmented using the Desikan–Killiany Atlas 27. 
For each of cortical regions, mean cortical thickness was calculated as the distance 
(in mm) between the pial and gray/white matter surfaces. A quality control of data 
was performed, the Pial and the white matter Surfaces were checked in order to 
remove any non brain tissue and non-white matter tissue respectively. The cortical 
thickness was smoothed with 10 mm FWHM Gaussian kernel to improve the signal-
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to-noise ratio and statistical power. 
 
Statistical Analysis 
Demographic, clinical and neuropsychological features were compared between 
subject groups (Placebo vs Donepezil). Chi-square test was performed on 
categorical variables, while the one-way analysis of variance (ANOVA) was utilized 
for continuous variables. Since the assumption of normality was violated, baseline 
cortical thicknesses measures were transformed according to a Two-Step Approach 
for Transforming Continuous Variables to Normal. The first step involves 
transforming the original variable toward statistical uniformity (i.e., satisfies the 
preponderance of diagnostics tests for uniformity) by calculating the fractional rank of 
each score, then fractional rank obtained from the previous step were transformed to 
normal using the inverse normal distribution function 28. Normalized baseline cortical 
thickness measures have been compared between groups using the ANOVA. 
Annualized Percentage Change (APC) of cortical thickness, in all the regions 
extracted from FreeSurfer pipeline, were computed as follows:  
 
Then, the cortical thickness APC were compared between placebo and donepezil 
using the Wilcoxon-Mann-Whitney test. 
The cortical thickness APC comparisons were supplemented post hoc by the linear 
mixed effects regression model with random intercepts, controlling for scanner 
platforms, to compare the difference in the cortical thickness change between 
placebo and donepezil patients in relation to treatment. Bonferroni correction for 
100
365

delayMRIbaselineatvalue
baselinefromchange
APC
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multiple comparisons was applied to the cortical thickness APC comparisons and to 
the mixed effect regression model results. The statistical analyses were performed 
using SPSS v.22.00.  
Surface analyses were performed using MATLAB (http://fr.mathworks.com) and the 
QDEC toolbox of FreeSurfer (www.surfer.nmr.mgh.harvard.edu). One-year changes 
in bilateral cortical structures were investigated using the Linear Mixed Effects 
Models. The results were projected onto the template. The surface analyses were re-
thresholded using a two-stage false discovery rate of 0.05 (FDR2 < 0.05). 
 
Power analysis 
Since the original Hippocampus Study trial was not designed for examine cortical 
thickness, an estimation of samples size needed to detect a thickness change of a 
certain number of millimetres between placebo and treatment patients was estimated. 
Sample size requirements were estimated using the following formula: 
2 ×  𝐾 ×  (
𝜎
𝜇1 – 𝜇2
)
2
, where K = constant, which is a function of α (0.05) and β=0.2 
(80%) ; σ is the standard deviation of cortical thickness APC in the untreated group,  
μ are the mean values of cortical thickness APC in the treatment and placebo groups. 
The following modification was included: the sample size thus derived was increased 
by 10% to allow for losses at follow-up.   
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Results 
From the total sample of 316 individuals (103 Placebo and 113 Donepzil) randomized 
in the trial, 174 individuals (92 Placebo and 82 Donepezil) underwent both baseline 
and follow-up MRI scans. One subject of them was excluded from analysis due to a 
corrupted scan. 
No significant differences were found at baseline sociodemographic as well as in 
cognitive features between groups (Table 1). The Apolipoprotein E (APOE) genotype 
was present in 18 (47.3%) patients in the placebo group and 18 (60%) in the 
donepezil showing no substantial differences (p = 0.215) between the two groups.  
The baseline cortical thickness, for all brain regions considered, did not show any 
significant statistical differences between the two groups (Table 2).  
As detailed in the Figure 1, a significant difference in the regional cortical thickness 
APC was observed between groups. In particular, the Placebo group compared with 
the Donepezil showed a higher APC in the right and left Rostral Anterior Cingulate 
Cortex -1.14% vs -0.38% (p = 0.048) and -1.28% vs 0.07% (p = 0.032) respectively, 
in the left Caudal Anterior Cingulate Cortex -1.07% vs 0.16% (p= 0.033), in the right 
and left Orbitofrontal Cortex -1.04% vs -0.001% (p = 0.012) and -0.54% vs 0.43% (p 
< 0.048) respectively, in the right Inferior Frontal Cortex -0.94% vs 0.23% (p = 0.022), 
and in the right Insula -1.06% vs 0.013% (p = 0.010).  
Post-hoc analysis by the mixed effects model (Figure 2) revealed that, during the 12 
months of treatment period, cortical thickness was significantly decreased in the 
Placebo group compared with the Donepezil in the in the right Lateral Orbitofrontal 
cortex (difference in slope 0.0023; p = 0.026), in the right Middle temporal Cortex 
(difference in slope 0.0027; p = 0.027) and in the right Insula (difference in slope 
0.0027; p = 0.015). Both the cortical thickness APC comparisons and the results on 
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the mixed effect model did not survived after Bonferroni correction. 
Surface differences were described in Figure 3 revealing a cortical thinning of 
Placebo group compared to the Donepezil in the Left Superior Temporal, Left 
Orbitofrontal, Right Supramarginal and Right Insula cortices. This result did not 
survive after FDR correction. 
Power analysis 
The mean (SD) cortical thickness APC for Donepezil group was -0.51 (2.18), while in 
the Placebo group was -0.95 (2.10). Based on these values, to have 80% power to 
detect a drug effect at 5% significance level (α= 0.05), 187 patients would be needed 
for each treatment arm. This assumes a 1 year-placebo-controlled trial with a 10% 
patients drop-out rate  
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Discussion 
To our knowledge, this is the first study investigating the effect of donepezil treatment 
on regional brain cortical thickness in suspected prodromal AD patients with amnestic 
syndrome of hippocampal type. Our results highlight the presence of a trend of 
stability in the cortical thickness APC in the Anterior Cingulate Cortex, in the left 
Orbitofrontal Cortex, in the Inferior Frontal Cortex, and in the right Insula in suspected 
prodromal AD patients treated with donepezil. These findings have been furthermore 
supported by data obtained from the Longitudinal Mixed Model and the cortical 
surface comparison of cortical thickness APC between groups. Indeed, we have 
found a trend of reduced cortical surface in the placebo group compared with the 
donepezil after one year of Donepezil treatment in the following regions: 
Orbitofrontal, Superior, and Caudal Middle Frontal Cortices, Superior Temporal, 
Supra Marginal, Precuneus, Inferior Parietal, and Insula. Some of these areas have 
been recognised to be of key importance since they are supposed to represent the 
cortical signature of Prodromal AD patients 29, 30. Although our results did not survive 
after multiple comparisons, they still remain promising since they have showed a 
statistical trend toward a significant impact of donepezil treatment in preserving 
cortical thickness in suspected prodromal AD patients. One possible reason 
explaining why our results did not survive to multiple comparison corrections might 
due to the fact that the sample power of the current study was not calculated for the 
present purpose but for the original aim of the Hippocampus Study Trial. Indeed, the 
necessary sample size to obtain a statistically significant effect in the cortical 
thickness APC between Placebo and Donepezil should be substantially higher, 187 
patients for each arm, as revealed by the sample power analysis. 
Notably, in line with a previous study revealing an increased resting state metabolism 
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in the left prefrontal cortex (and in the right hippocampus) of AD patients treated with 
Donepezil 11, we also found a significant reduced cortical thinning in left Orbitofrontal 
Cortex and Anterior Cingulate Cortex in this group.  
Previous studies investigating the donepezil effect on different structural imaging 
markers, such as the hippocampus, the brain lateral ventricles, and the whole brain 
volumes, showed contrasting results. A randomized double-blind, placebo-controlled 
mono-center study on 67 patients with mild-to-moderate AD found a small decrease 
in left hippocampal volume after 24-week of donepezil compared with the placebo-
treated subjects 31. Results from the Alzheimer's Disease Cooperative Study (ADCS) 
MCI Donepezil/Vitamin E study conducted on 131 MCI patients showed a statistical 
trend towards a possible slowing of the hippocampal atrophy rate by donepezil 12. A 
more recent study conducted by Schuff and colleagues 32 on aMCI subjects reported 
significant differences in favour of the donepezil group for the total ventricular region 
and the cortical region (whole brain volumes) but not for the hippocampal volume. 
Recently, our group confirmed the data by Schuff and colleagues 32 for ventricular 
and whole brain volumes. In addition, we observed a significant reduction in the 
annual rate of hippocampal atrophy in suspected prodromal AD patients treated with 
donepezil 33.  
Regional cortical thickness reduction is used as a predictive indicator of AD-related 
neurodegeneration in MCI subjects 30, 34. Our results revealed unilateral treatment 
differences in several brain regions that might be due to normal variation and 
specialization of function and structure. Brain asymmetry is believed to be 
evolutionally adaptive, reducing possible interference between hemispheres 35. 
Based on the hypothesis that donepezil may attenuate amyloid-induced neuronal 
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toxicity 36, 37, it is conceivable that 12 months of donepezil treatment might have a 
neuroprotective effect on the cortex. In vitro studies demonstrated that lesions of the 
cholinergic nucleus basalis of Meynert promote the ex vivo synthesis of Aβ precursor 
protein (AβPP) in the cerebral cortex 38. Recently, an in vivo neuroimaging study 
described a correlation between basal forebrain atrophy and elevated cortical 
amyloid load in preclinical and pre-dementia stages of AD 39, thus reflecting the 
association found in several human autopsy studies between amyloid pathology and 
cholinergic atrophy in AD 40, 41, 42. Cortical amyloid accumulation might induce 
cholinergic cell death involving alterations in the levels of intracellular calcium and/or 
production of toxic and inflammatory mediators such as nitric oxide, cytokines, and 
reactive oxygen intermediates 43. On the other hand, a cholinergic stimulation alters 
positively the mechanisms of amyloid processing, thus protecting neurons from 
neurodegeneration induced by Aβ 36. 
In this study, we found a trend toward a statistical significance for cortical thinning 
reduction in the cortical areas innervated by the medial and lateral cholinergic 
pathways 44 in suspected prodromal AD patients receiving one year of donepezil 
treatment.  
One of the main strengths of the present study is the refined target population 
deriving from a large-scale community-based multi-centre cohort of subjects included 
on the basis of the FCSRT, a memory test reported to be highly correlated with 
hippocampal volume and CSF levels changes of the Alzheimer type 18, 19. 
The study presents potential limitations. First of all, the data used in the present 
research were not specifically powered for the aims of the present study, thus 
reducing the significance of the results.  The protocol of the study did not include 
information on the settings of the subjects of the population or on race and ethnicity 
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characteristics or data in terms of lifestyle. The latter, in particular, given its practical 
aspects – nutrition, hydration, and physical activity – has become significant in terms 
of AD prevention. We did not collect sufficient data on APOE ε4 genotype to exclude 
the hypothesis that our results were not significantly impacted by the presence of 
APOE ε4 genotype. Finally, the subjects have not been followed for a long enough 
period of time in order to determine the incidence of incipient AD in each group.  
Overall, our findings support the hypothesis that cortical thickness might be used as 
surrogate outcome in pre-dementia AD clinical trials. Moreover, our findings suggest 
that donepezil may have an impact on cortical morphology in prodromal AD patients. 
A potentially disease-modifying effect of approved cholinesterase inhibitors 
represents a result of pivotal clinical interest. Further studies are needed to confirmed 
this first investigation. Moreover, established measurement of the basal forebrain 
cholinergic nuclei volume, such as the nucleus basalis of Meynert and its subnuclei, 
as well as their in vivo white matter connections to subcortical and cortical areas, are 
of interest to detect the specific donepezil effect on the brain’s cholinergic system.  
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Clinical Points 
 
 Cortical thickness measurements may represent reliable surrogate markers of 
disease progression and underlying Alzheimer’s Disease at prodromal stages 
 Our data indicate that Donepezil treatment may reduce cortical thickness 
annualized percent changes mainly in cortical areas associated to the 
cholinergic system supporting the hypothesis that Donepezil may impact on 
brain structure/morphology 
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Figures 
 
Figure 1. Significant differences in the Left and Right Brain Cortical Thickness 
Annualized Percentage Changes. Patients treated with Donepezil showed an 
increase or stable change of the frontal and insula cortical thicknesses compared to 
the Placebo group revealing a cortical thinning in all the cortical regions. Numbers 
indicate means (errors standard) of Annual Percentage Change; p values denote the 
significance at Wilcoxon-Mann-Whitney test. 
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Figure 2. Individual trajectories of Cortical Thickness change. Graphs display 
significant changes over time resulted from the Linear Mixed Effects regression 
Models with random intercepts in the donepezil and placebo groups based on cortical 
thickness measurements from baseline (Month 0) to follow-up scan.  
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Figure 3. Surface differences between placebo and donepezil groups detected 
by the Linear Mixed Effects Model, results are FDR uncorrected.  
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Tables 
Table 1: Baseline Demographic and Clinical Characteristics of patients 
performing baseline and follow-up MRI. Means and standard deviations are 
reported for continuous variables, numbers and percentages for the dichotomous 
ones. P-values denote significant differences at ANOVA and Chi-square tests. 
 Placebo 
(n = 92) 
Donepezil 
(n = 81) 
P Value 
Age, years 73.17 (6.63) 73.24 (6.67) 0.966 
Sex, n (%)  
Male  
Female  
 
44 (47.8) 
48 (52.1) 
 
39 (48.1) 
42 (51.8) 
 
0.544 
APOE ε4 carriers, n (%) 
Missing 
18 (47.3) 
54 
18 (60) 
43 
0.215 
Education, n (%) 
No education 
Primary  
Certificate of Primary Education  
Secondary  
Higher education 
 
1 (0.01) 
7 (7.6) 
43 (46.7) 
14 (15.2) 
27 (29.3) 
 
0 (0.0) 
8 (9.8) 
30 (37) 
21 (25.9) 
22 (27.1) 
 
0.330 
Follow-up MRI (months) 9.65 (4.78) 10.07 (4.43) 0.537 
FCSRT (Free recall) 11.32 (5.61) 12.21 (5.40) 0.289 
FCSRT (Total recall) 29.55 (9.93) 31.37 (8.91) 0.210 
Hamilton Rating Scale for 
Depression  
3.22 (2.94) 2.83 (2.49) 0.352 
  
30 
ADAS-COG-MCI 
 
12.32 (4.40) 12.32 (4.61) 0.997 
MMSE  25.86 (2.79) 25.94 (2.26)  0.838 
3 Tesla MRI (%) 22 (23%) 23 (28%) 0.534 
Abbreviations: APOE= Apolipoprotein E, FCSRT= Free and Cued Selective 
Reminding Test, MRI= Magnetic Resonance Imaging. 
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Table 2:  Baseline Right and Left Cortical thickness (mm) of 173 patients. 
Means and standard deviations are reported, P Values denote significant differences 
at ANOVA. 
 Left Hemisphere Right Hemisphere 
 Placebo  
(n = 92) 
Donepezil  
(n = 81) 
p-value 
 
Placebo  
(n = 92) 
Donepezil  
(n = 81) 
P 
Value 
 
Cingulate Cortex       
Rostral Anterior 2.74±0.02 2.80±0.02 0.113 2.72±0.02 2.75±0.03 0.698 
Caudal Anterior 2.57±0.03 2.60±0.04 0.820 2.57±0.03 2.68±0.03 0.064 
Posterior 2.31±0.01 2.34±0.02 0.452 2.31±0.02 2.34±0.02 0.345 
Isthimus 2.15±0.02 2.17±0.01 0.337 2.12±0.01 2.14±0.02 0.538 
Frontal Lobe       
Pre-central 2.32±0.01 2.35±0.01 0.355 2.34±0.01 2.35±0.01 0.664 
Superior Frontal 2.49±0.01 2.50±0.01 0.996 2.51±0.01 2.51±0.01 0.560 
Middle Frontal Caudal 2.33±0.01 2.35±0.01 0.350 2.37±0.01 2.38±0.01 0.985 
Middle Frontal Rostral 2.20±0.01 2.22±0.01 0.472 2.21±0.01 2.23±0.01 0.823 
Inferior Frontal Pars 
Orbitalis 
2.51±0.02 2.54±0.02 0.255 2.49±0.02 2.45±0.02 0.239 
Inferior Frontal Pars 
Triangularis 
2.27±0.01 2.27±0.01 0.941 2.26±0.01 2.24±0.01 0.392 
Inferior Frontal Pars 
Opercularis 
2.38±0.01 2.39±0.01 0.557 2.40±0.01 2.40±0.01 0.887 
Frontal Pole 2.61±0.03 2.65±0.03 0.192 2.67±0.03 2.66±0.03 0.916 
Orbitofrontal Lateral 2.45±0.01 2.44±0.01 0.892 2.44±0.01 2.44±0.01 0.607 
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Orbitofrontal Medial 2.36±0.02 2.36±0.01 0.308 2.34±0.01 2.36±0.01 0.143 
Parietal       
Post-Central 1.95±0.01 1.99±0.02 0.460 1.98±0.01 2.00±0.01 0.472 
Supra Marginal 2.31±0.01 2.32±0.01 0.885 2.33±0.01 2.34±0.01 0.848 
Superior Parietal 2.01±0.01 2.04±0.01 0.182 2.05±0.01 2.06±0.01 0.814 
Inferior Parietal 2.22±0.01 2.26±0.01 0.166 2.22±0.01 2.25±0.01 0.164 
Precuneus 2.12±0.01 2.14±0.01 0.541 2.12±0.01 2.13±0.01 0.798 
Temporal       
Inferior Temporal 2.56±0.01 2.58±0.02 0.447 2.57±0.01 2.57±0.01 0.986 
Superior Temporal 2.5±0.1 2.5±0.1 0.980 2.5±0.1 2.5±0.1 0.852 
Transverse Temporal 2.25±0.02 2.22±0.02 0.770 2.26±0.02 2.27±0.02 0.824 
Middle Temporal 2.59±0.01 2.60±0.01 0.778 2.56±0.01 2.55±0.01 0.504 
Temporal Pole 3.3±0.3 3.2±0.3 0.376 3.32±0.04 3.31±0.03 0.991 
Entorhinal 2.94±0.04 2.88±0.04 0.554 2.84±0.05 2.87±0.04 0.669 
Para-hippocampal 2.38±0.03 2.41±0.03 0.936 2.34±0.02 2.28±0.04 0.498 
Fusiform 2.43±0.01 2.45±0.01 0.322 2.41±0.01 2.43±0.01 0.270 
Occipital       
Lateral Occipital 2.03±0.01 2.05±0.01 0.713 2.02±0.01 2.03±0.01 0.887 
Cuneus 1.75±0.01 1.78±0.01 0.250 1.74±0.01 1.75±0.01 0.725 
Peri-Calcarine 1.56±0.01 1.56±0.01 0.940 1.51±0.01 1.51±0.01 0.702 
Lingual 1.85±0.01 1.86±0.01 0.718 1.83±0.01 1.82±0.01 0.889 
Insula 2.81±0.01 2.80±0.01 0.748 2.86±0.01 2.82±0.02 0.111 
 
 
